Alexithymia has no clinically relevant association with outcome of multimodal treatment tailored to needs of patients suffering from somatic symptom and related disorders: A clinical prospective study

L. de Vroege, W.H.M. Emons, K. Sijtsma, C.M. van der Feltz-Cornelis

Research output: Contribution to journalArticleScientificpeer-review

9 Downloads (Pure)

Abstract

Introduction
Alexithymia may moderate the effectiveness of treatment and may predict impaired general functioning of patients suffering from somatic symptom and related disorders (SSRD).
Aim
We compared alexithymia levels in a clinical prospective study with 234 consecutive patients suffering from SSRD from the Centre of Excellence for Body, Mind, and Health, Tilburg using the Bermond-Vorst Alexithymia Questionnaire, with general population norm scores. Second, we explored treatment outcomes of a multimodal treatment tailored to patient needs by Shared Decision Making (SDM) and Patient Related Outcome Monitoring (PROM) in patients with SSRD. Third, we explored whether alexithymia is associated with treatment outcome. Fourth, we explored if the presence of a chronic medical condition (e.g., diabetes mellitus, cardiovascular diseases) affects the association of alexithymia with treatment outcomes.
Results
Compared to norm scores, SSRD patients showed elevated scores on the subscales identifying, verbalizing, and fantasizing, and on the cognitive dimension. All patients benefited from treatment in terms of anxiety, depression, and physical symptoms. The association of alexithymia with treatment outcome was significant, but the effect size was negligible (range odds ratios 1.02 – 1.25). The association between alexithymia and treatment outcome was stronger in patients suffering from chronic medical conditions compared to patients without chronic medical conditions. However, the effect size of this association was negligible (range odds ratio 0.94 – 1.12).
Discussion
Alexithymia scores are elevated in patients with SSRD compared with general population scores, but the level of alexithymia has no clinically relevant association with treatment outcome both in SSRD patients with and without comorbid chronic medical conditions.
Original languageEnglish
Article number292
Number of pages11
JournalFrontiers in Psychiatry
Volume9
DOIs
Publication statusPublished - 2018

Fingerprint

Affective Symptoms
Odds Ratio
Medically Unexplained Symptoms
Physiologic Monitoring
Diabetes Mellitus
Depression

Keywords

  • CHRONIC PAIN
  • GENERAL-POPULATION
  • INFLAMMATORY-BOWEL-DISEASE
  • PSYCHOLOGICAL INTERVENTION
  • PSYCHOMETRIC PROPERTIES
  • QUALITY-OF-LIFE
  • QUESTIONNAIRE
  • SCALE
  • SOMATOFORM
  • VALIDITY
  • alexithymia
  • anxiety
  • depression
  • general functioning
  • physical symptoms
  • somatic symptom and related disorders
  • treatment outcome

Cite this

@article{a6928b0a3d154981b1cdf2e8b9c2ad66,
title = "Alexithymia has no clinically relevant association with outcome of multimodal treatment tailored to needs of patients suffering from somatic symptom and related disorders: A clinical prospective study",
abstract = "IntroductionAlexithymia may moderate the effectiveness of treatment and may predict impaired general functioning of patients suffering from somatic symptom and related disorders (SSRD). AimWe compared alexithymia levels in a clinical prospective study with 234 consecutive patients suffering from SSRD from the Centre of Excellence for Body, Mind, and Health, Tilburg using the Bermond-Vorst Alexithymia Questionnaire, with general population norm scores. Second, we explored treatment outcomes of a multimodal treatment tailored to patient needs by Shared Decision Making (SDM) and Patient Related Outcome Monitoring (PROM) in patients with SSRD. Third, we explored whether alexithymia is associated with treatment outcome. Fourth, we explored if the presence of a chronic medical condition (e.g., diabetes mellitus, cardiovascular diseases) affects the association of alexithymia with treatment outcomes. ResultsCompared to norm scores, SSRD patients showed elevated scores on the subscales identifying, verbalizing, and fantasizing, and on the cognitive dimension. All patients benefited from treatment in terms of anxiety, depression, and physical symptoms. The association of alexithymia with treatment outcome was significant, but the effect size was negligible (range odds ratios 1.02 – 1.25). The association between alexithymia and treatment outcome was stronger in patients suffering from chronic medical conditions compared to patients without chronic medical conditions. However, the effect size of this association was negligible (range odds ratio 0.94 – 1.12).DiscussionAlexithymia scores are elevated in patients with SSRD compared with general population scores, but the level of alexithymia has no clinically relevant association with treatment outcome both in SSRD patients with and without comorbid chronic medical conditions.",
keywords = "CHRONIC PAIN, GENERAL-POPULATION, INFLAMMATORY-BOWEL-DISEASE, PSYCHOLOGICAL INTERVENTION, PSYCHOMETRIC PROPERTIES, QUALITY-OF-LIFE, QUESTIONNAIRE, SCALE, SOMATOFORM, VALIDITY, alexithymia, anxiety, depression, general functioning, physical symptoms, somatic symptom and related disorders, treatment outcome",
author = "{de Vroege}, L. and W.H.M. Emons and K. Sijtsma and {van der Feltz-Cornelis}, C.M.",
year = "2018",
doi = "10.3389/fpsyt.2018.00292",
language = "English",
volume = "9",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Alexithymia has no clinically relevant association with outcome of multimodal treatment tailored to needs of patients suffering from somatic symptom and related disorders

T2 - A clinical prospective study

AU - de Vroege, L.

AU - Emons, W.H.M.

AU - Sijtsma, K.

AU - van der Feltz-Cornelis, C.M.

PY - 2018

Y1 - 2018

N2 - IntroductionAlexithymia may moderate the effectiveness of treatment and may predict impaired general functioning of patients suffering from somatic symptom and related disorders (SSRD). AimWe compared alexithymia levels in a clinical prospective study with 234 consecutive patients suffering from SSRD from the Centre of Excellence for Body, Mind, and Health, Tilburg using the Bermond-Vorst Alexithymia Questionnaire, with general population norm scores. Second, we explored treatment outcomes of a multimodal treatment tailored to patient needs by Shared Decision Making (SDM) and Patient Related Outcome Monitoring (PROM) in patients with SSRD. Third, we explored whether alexithymia is associated with treatment outcome. Fourth, we explored if the presence of a chronic medical condition (e.g., diabetes mellitus, cardiovascular diseases) affects the association of alexithymia with treatment outcomes. ResultsCompared to norm scores, SSRD patients showed elevated scores on the subscales identifying, verbalizing, and fantasizing, and on the cognitive dimension. All patients benefited from treatment in terms of anxiety, depression, and physical symptoms. The association of alexithymia with treatment outcome was significant, but the effect size was negligible (range odds ratios 1.02 – 1.25). The association between alexithymia and treatment outcome was stronger in patients suffering from chronic medical conditions compared to patients without chronic medical conditions. However, the effect size of this association was negligible (range odds ratio 0.94 – 1.12).DiscussionAlexithymia scores are elevated in patients with SSRD compared with general population scores, but the level of alexithymia has no clinically relevant association with treatment outcome both in SSRD patients with and without comorbid chronic medical conditions.

AB - IntroductionAlexithymia may moderate the effectiveness of treatment and may predict impaired general functioning of patients suffering from somatic symptom and related disorders (SSRD). AimWe compared alexithymia levels in a clinical prospective study with 234 consecutive patients suffering from SSRD from the Centre of Excellence for Body, Mind, and Health, Tilburg using the Bermond-Vorst Alexithymia Questionnaire, with general population norm scores. Second, we explored treatment outcomes of a multimodal treatment tailored to patient needs by Shared Decision Making (SDM) and Patient Related Outcome Monitoring (PROM) in patients with SSRD. Third, we explored whether alexithymia is associated with treatment outcome. Fourth, we explored if the presence of a chronic medical condition (e.g., diabetes mellitus, cardiovascular diseases) affects the association of alexithymia with treatment outcomes. ResultsCompared to norm scores, SSRD patients showed elevated scores on the subscales identifying, verbalizing, and fantasizing, and on the cognitive dimension. All patients benefited from treatment in terms of anxiety, depression, and physical symptoms. The association of alexithymia with treatment outcome was significant, but the effect size was negligible (range odds ratios 1.02 – 1.25). The association between alexithymia and treatment outcome was stronger in patients suffering from chronic medical conditions compared to patients without chronic medical conditions. However, the effect size of this association was negligible (range odds ratio 0.94 – 1.12).DiscussionAlexithymia scores are elevated in patients with SSRD compared with general population scores, but the level of alexithymia has no clinically relevant association with treatment outcome both in SSRD patients with and without comorbid chronic medical conditions.

KW - CHRONIC PAIN

KW - GENERAL-POPULATION

KW - INFLAMMATORY-BOWEL-DISEASE

KW - PSYCHOLOGICAL INTERVENTION

KW - PSYCHOMETRIC PROPERTIES

KW - QUALITY-OF-LIFE

KW - QUESTIONNAIRE

KW - SCALE

KW - SOMATOFORM

KW - VALIDITY

KW - alexithymia

KW - anxiety

KW - depression

KW - general functioning

KW - physical symptoms

KW - somatic symptom and related disorders

KW - treatment outcome

U2 - 10.3389/fpsyt.2018.00292

DO - 10.3389/fpsyt.2018.00292

M3 - Article

VL - 9

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

M1 - 292

ER -